HTA Quarterly | Summer 2018

By Xcenda

We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.

HTA QUARTERLY | SUMMER 2018

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

Value assessment frameworks (VAFs) are systematic approaches for the evaluation of health technologies that may assist stakeholders in understanding the value of a technology. Existing VAFs are sufficient to account for some value components, but they struggle to account for a changing landscape that may involve the introduction of new indications and new comparators. We provide an overview of the current challenges and barriers with current VAFs in VBP and to raise awareness of potential opportunities and solutions.
Oral medication with pricing data and a calculator

HTA QUARTERLY | SUMMER 2018

The European Medicines Agency to Find a New Home After Brexit

In June 2016, the United Kingdom voted in a referendum to leave the European Union. "Brexit," as it's known, includes the move of two UK-based EU agencies, the European Medicines Agency (EMA) and the European Banking Authority (EBA) to a location within the remaining EU member states. This article looks to answer some key questions regarding the departure of the EMA from its London-based headquarters and the effect that this move could have on UK-based pharmaceutical manufacturers and the UK’s current status as an important player on the global drug development stage.
EMA Logo

HTA QUARTERLY | SUMMER 2018

Top Trends in Health Policy in Canada: Insights from InnomarLive

In April 2018, InnomarConsulting, part of AmerisourceBergen, hosted their 8th semi-annual InnomarLive Conference, Top Trends in Health Policy. The forum was held to discuss the rapid changes in healthcare policy and the impact on the healthcare landscape in Canada, now and in the future. The expert panelists provided insights on the opportunities and challenges faced by private payers and the pharmaceutical industry; pricing trends, including outcomes based agreements, and updates from PMPRB, pCPA, pCODR, and INESSS; and how these changes affect all stakeholders.
Canadian flag

Heard on the Street

For the reasons described previously, it is critical that information provided by firms about their unapproved products and about unapproved uses of approved/cleared products be truthful and non-misleading.

– DRUG AND DEVICE MANUFACTURER COMMUNICATION WITH PAYORS, FORMULARY COMMITTEES, AND SIMILAR ENTITIES        – FDA GUIDANCE FOR INDUSTRY AND REVIEW STAFF.

HTA by the Numbers

£2.5 Billion

$3.6 Billion